167 related articles for article (PubMed ID: 37954147)
1. The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging 'nonmutational epigenetic reprogramming' cancer hallmark.
Fasano C; Lepore Signorile M; Di Nicola E; Pantaleo A; Forte G; De Marco K; Sanese P; Disciglio V; Grossi V; Simone C
Comput Struct Biotechnol J; 2023; 21():5240-5248. PubMed ID: 37954147
[TBL] [Abstract][Full Text] [Related]
2. Identifying novel SMYD3 interactors on the trail of cancer hallmarks.
Fasano C; Lepore Signorile M; De Marco K; Forte G; Sanese P; Grossi V; Simone C
Comput Struct Biotechnol J; 2022; 20():1860-1875. PubMed ID: 35495117
[TBL] [Abstract][Full Text] [Related]
3. SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage.
Lepore Signorile M; Sanese P; Di Nicola E; Fasano C; Forte G; De Marco K; Disciglio V; Latrofa M; Pantaleo A; Varchi G; Del Rio A; Grossi V; Simone C
Cells; 2023 Nov; 12(22):. PubMed ID: 37998381
[TBL] [Abstract][Full Text] [Related]
4. SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Bottino C; Peserico A; Simone C; Caretti G
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935919
[TBL] [Abstract][Full Text] [Related]
5. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
6. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
7. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.
Hayashi M; Deng L; Chen M; Gan X; Shinozaki K; Shoji I; Hotta H
Microbiol Immunol; 2016 Jan; 60(1):17-25. PubMed ID: 26616333
[TBL] [Abstract][Full Text] [Related]
9. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
Bai H; Li Y; Gao H; Dong Y; Han P; Yu H
Cytotechnology; 2016 Aug; 68(4):849-59. PubMed ID: 25563599
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
[No Abstract] [Full Text] [Related]
12. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.
Proserpio V; Fittipaldi R; Ryall JG; Sartorelli V; Caretti G
Genes Dev; 2013 Jun; 27(11):1299-312. PubMed ID: 23752591
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
14. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
15. Smyd3-associated regulatory pathways in cancer.
Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
[TBL] [Abstract][Full Text] [Related]
16. Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy.
Zhu HP; Chai J; Qin R; Leng HJ; Wen X; Peng C; He G; Han B
Eur J Med Chem; 2023 Jan; 246():115009. PubMed ID: 36527933
[TBL] [Abstract][Full Text] [Related]
17. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
Peserico A; Germani A; Sanese P; Barbosa AJ; Di Virgilio V; Fittipaldi R; Fabini E; Bertucci C; Varchi G; Moyer MP; Caretti G; Del Rio A; Simone C
J Cell Physiol; 2015 Oct; 230(10):2447-2460. PubMed ID: 25728514
[TBL] [Abstract][Full Text] [Related]
18. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
19. Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Sanese P; Fasano C; Buscemi G; Bottino C; Corbetta S; Fabini E; Silvestri V; Valentini V; Disciglio V; Forte G; Lepore Signorile M; De Marco K; Bertora S; Grossi V; Guven U; Porta N; Di Maio V; Manoni E; Giannelli G; Bartolini M; Del Rio A; Caretti G; Ottini L; Simone C
iScience; 2020 Oct; 23(10):101604. PubMed ID: 33205017
[No Abstract] [Full Text] [Related]
20. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
